Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FZOCUS-2: Fluzoparib Maintenance in Recurrent Ovarian Cancer
NCT03863860Phase 3Completed
- Sponsor
- Hengrui
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Fluzoparib with Placebo (2 arms). Primary endpoints: Progression-Free Survival up to 2 years and Progression-Free Survival in BRCA mutant patients up to 2 years. Started Apr 2019; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03863860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863860.